Research Team Confirms Safety of Alzheimer’s Drug Lecanemab
Tokyo, March 25 (Jiji Press)–More than 90 pct of patients receiving Lecanemab, an Alzheimer’s drug, in hospitals across Japan have been able to continue treatment without strong side effects, a group of researchers in the country said. Lecanemab, developed by Eisai Co.